The New Approach to Schizophrenia: An Honest Conversation About Cobenfy

Autumn Roque, DNP, APRN, PMHNP-BC, and Michael Asbach, DMSc, PA-C, Psych-CAQ, have an honest conversation about xanomeline/trospium (Cobenfy, formerly known as KarXT. Unlike most available antipsychotics, xanomeline/trospium utilizes a unique mechanism of action and does not directly block D2 dopamine receptors. While this is a much needed step of innovation, what hesitations do Roque and Asbach have concerning this new treatment option?

To hear more from Roque and Asbach, be sure to check out their Clinician's Corner columns:

To Be or Not to Be? Understanding False Positives in Bipolar Diagnosis

Depression With Anhedonia vs Dysthymia: Do We Understand the Difference?

Ms Roque is a clinical associate professor in the Hahn School of Nursing and Health Science at the University of San Diego. Mr Asbach is a psychiatric physician associate and serves as associate director of interventional psychiatry at DENT Neurologic Institute in New York.